ASX:WBC 18 May 2026

NAB Shares Rebound; Watch for What’s Next for Big Australian Banks
·······

NAB Shares Rebound; Watch for What’s Next for Big Australian Banks

National Australia Bank shares rose 1.98% to A$37.04 on Tuesday, rebounding from a 52-week low hit Monday. The move followed Reserve Bank of Australia minutes suggesting room to pause on rate hikes. Inflation, energy shocks, and bad-debt risks continue to weigh on the sector. NAB’s first-half cash earnings recently missed estimates, partly due to a A$706 million credit impairment charge.
May 19, 2026
ANZ Shares Slip Again, And Tuesday’s RBA Signals May Decide What Comes Next
·······

ANZ Shares Slip Again, And Tuesday’s RBA Signals May Decide What Comes Next

ANZ closed Monday at A$35.06, down 0.43%, as the S&P/ASX 200 dropped 1.45% to a seven-week low amid oil and inflation concerns. ANZ’s standard variable home loan rate rose to 8.64% from May 15. The Reserve Bank of Australia holds its cash rate at 4.35%, with meeting minutes due Tuesday. Financials fell less than the broader market, but ANZ shares still declined.
May 18, 2026
CBA Bounces, but Australia Bank Rout Leaves Traders Asking What’s Next
·······

CBA Bounces, but Australia Bank Rout Leaves Traders Asking What’s Next

Commonwealth Bank of Australia shares rose 0.84% to A$160.74 Monday, bucking a 1.45% drop in the S&P/ASX 200. The gain followed last week’s record 10.43% one-day fall after CBA raised loan-loss provisions by A$200 million. CBA also named Professor Mary-Anne Williams its first Chief AI Scientist. The broader market hit a seven-week low as energy was the only sector to advance.
May 18, 2026

Stock Market Today

  • Aroa Biosurgery Exceeds FY26 Revenue Guidance Driven by 54% Growth in Myriad Product
    May 26, 2026, 2:07 AM EDT. Aroa Biosurgery reported FY26 revenue of NZ$103.9 million, surpassing guidance and marking a 23% increase from FY25. The flagship Myriad wound care product line surged 54% to NZ$49.5 million, boosting normalised EBITDA to NZ$12.6 million, well beyond the forecasted NZ$5-8 million range. Direct sales now make up 59% of revenue, growing fastest among sales channels, while partner sales contributed 41%. The company ended FY26 debt-free with NZ$27.1 million in cash and provided FY27 revenue guidance of NZ$115-125 million. Gross margins held steady despite manufacturing cost pressures. Aroa's strong cash flow and strategic partnerships underpin its stable market position and continued investment in clinical development.